PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
December 5, 2025Diabetes/Metabolism Research and ReviewsOpen Access

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYizhu ChenYTYufei TangRYRui Yue

Discussion

Loading...

Member takes

Overview

Systematic review demonstrates GLP-1 receptor agonists reduce blood pressure and improve glycosylated haemoglobin in type 1 diabetes, indicating potential for better management.

Key Points

  • GLP-1 receptor agonists significantly reduced systolic blood pressure by 2.65 mmHg in type 1 diabetes patients.
  • Utilizing 21 randomized controlled trials, the study reported improvements in glycosylated haemoglobin and body mass index.
  • This systematic review emphasizes the beneficial effects of GLP-1 receptor agonists on multiple cardiometabolic risk factors.
  • Adjuvant therapy with GLP-1 receptor agonists offers a promising approach for managing type 1 diabetes effectively.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/693231288e51979591dce4b2https://doi.org/10.1002/dmrr.70111
View Full Paper
Ask AI
Bookmark
Share